Immune Thrombocytopenia: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
'''For patient information, click [[Xyz (patient information)|here]]''' | '''For patient information, click [[Xyz (patient information)|here]]''' | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} | ||
{{SK}} | |||
==[[Xyz overview|Overview]]== | ==[[Xyz overview|Overview]]== | ||
==[[Xyz historical perspective|Historical Perspective]]== | ==[[Xyz historical perspective|Historical Perspective]]== | ||
==[[Xyz classification|Classification]]== | ==[[Xyz classification|Classification]]== | ||
Revision as of 23:21, 8 December 2020
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Immune Thrombocytopenia On the Web |
|
American Roentgen Ray Society Images of Immune Thrombocytopenia |
|
Risk calculators and risk factors for Immune Thrombocytopenia |
For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Synonyms and keywords:
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Xyz from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Interventions | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies